STOCK TITAN

TScan Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biopharmaceutical company, will participate in a fireside chat at the 2022 Jefferies Healthcare Conference on June 9, 2022, at 9:30 a.m. ET in New York. This event will focus on TCR engineered T cell therapies for cancer treatment. Interested parties can access the live webcast on the Company's website, with an archived replay available for 30 days post-event. TScan's lead therapies, TSC-100 and TSC-101, aim to treat hematologic malignancies and prevent leukemia relapse post-transplant.

Positive
  • None.
Negative
  • None.

WALTHAM, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that management will participate in a fireside chat at the 2022 Jefferies Healthcare Conference being held at the Marriott Marquis in New York, NY on Thursday, June 9, 2022 at 9:30 a.m. ET.

A webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at www.ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 30 days following the event.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead leukemia TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types in order to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.

Contacts:

Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com

Joyce Allaire
LifeSci Advisors, LLC
Managing Director
617-435-6602
jallaire@lifesciadvisors.com 


FAQ

When will TScan Therapeutics participate in the Jefferies Healthcare Conference?

TScan Therapeutics will participate in the Jefferies Healthcare Conference on June 9, 2022, at 9:30 a.m. ET.

Where can I watch the TScan Therapeutics fireside chat?

The fireside chat can be watched live on TScan Therapeutics' website under the 'Events and Presentations' section.

What are TScan Therapeutics' lead therapies focused on?

TScan's lead therapies, TSC-100 and TSC-101, are focused on treating hematologic malignancies and preventing leukemia relapse after stem cell transplantation.

How long will the TScan Therapeutics webcast be available?

The archived replay of the TScan Therapeutics webcast will be available for 30 days following the event.

What is the focus of TScan Therapeutics as a company?

TScan Therapeutics focuses on developing T cell receptor engineered therapies for cancer treatment.

TScan Therapeutics, Inc.

NASDAQ:TCRX

TCRX Rankings

TCRX Latest News

TCRX Stock Data

240.50M
48.70M
0.88%
99.58%
4.24%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
WALTHAM